India Biotech Group Questions Approval Of Cipla's First Biosimilar
This article was originally published in PharmAsia News
Executive Summary
India's Association of Biotechnolegy Led Enterprises questions government approval of Cipla's recently launched Etacept (etanercept) for rheumatism as its first biosimilar drug, suggesting it may not have followed guidelines.